The strange thing about Alan’s €480 million is not the size, it is the clock. The Paris health insurer raised €100 million at a €5 billion valuation in March, and roughly three months later it has raised almost five times that at €5.5 billion, lifting its total funding past €1.2 billion. Companies that need money that often are usually bleeding it. Alan is profitable in France, which makes raising twice in a single quarter the kind of move that asks for an explanation rather than supplying one.

The new round is a Series G led by Prosus, the Amsterdam-listed investment arm of Naspers, with existing backers Index Ventures and Teachers’ Venture Growth returning and a new investor, Dara Holdings, joining. According to the Financial Times the Prosus cheque mixes fresh capital with the purchase of secondary shares, and the whole thing still needs sign-off from France’s financial regulators, because insurers do not close rounds the way pure software firms do. That regulatory tail is itself a reminder of what Alan actually is underneath the app: a licensed insurer carrying reserves, not a SaaS company booking subscriptions.

The case for the money is the reserves, not the runway

Alan’s numbers are the part that makes a late-stage cheque make sense. It passed €800 million in annual recurring revenue in the first quarter of 2026, up 53% year on year, serves more than 1.1 million members and 37,000 businesses, and employs over 850 people across France, Spain, Belgium and Canada. Member satisfaction sits above 4.2 out of 5, and most reimbursements clear within a day. Crucially it is profitable in its home market, which in a category where insurtechs traditionally burn cash for the better part of a decade is the rarer achievement than the valuation.

The model is capital-hungry by design, and that is the honest reason a profitable company keeps raising. Insurance demands reserves against the policies it writes, and every new country demands more of them before a single member is signed. A profitable France gives Alan a cushion that pure-growth rivals lack, but expansion into markets where it has no brand, no regulatory history and no distribution still has to be funded up front. The €480 million is less a runway extension than working capital for a balance-sheet business that has decided to grow into four more flags.

Founded in 2016 by Jean-Charles Samuelian-Werve and Charles Gorintin, an early Facebook, Instagram and Twitter engineer, Alan began as a digital health insurer in a French market that had not licensed a new independent one since 1986. Samuelian-Werve also had a hand in starting Mistral, the French model lab that has become the country’s standard answer to the question of whether Europe can build its own frontier AI, which is the sort of overlapping founder résumé that tells you how small the serious end of French tech still is.

Prevention is a nice word until someone has to underwrite it

What Alan is actually selling with this round is a category name. It calls its model “prevention insurance,” bundling health cover, care navigation, wellbeing services and an AI health assistant into one app, with the pitch that the system should act before illness rather than after it. Its AI handles underwriting, claims and member engagement, which is how a company keeps headcount flat while revenue grows 53%. The bet is that owning the whole stack, payer and provider and prevention layer at once, produces better outcomes and lower long-term cost than the fragmented incumbents it is trying to replace.

The reasons to doubt are specific and old. Insurers have promised to reward healthy behaviour and pay for prevention for years, and the results have been mixed at best, because turning app nudges and a chatbot into measurably better health, at scale, across a million members, is genuinely hard and rarely demonstrated. Alan has the engagement numbers and the satisfaction scores. What it does not yet have, and what no insurer in this space has, is durable proof that prevention spending today lowers the claims bill enough tomorrow to justify the model rather than just the marketing. The category it is naming is real as a product. It is still a wager as economics.

Prosus is the tell on the other side of the table. Best known for an early Tencent stake and a string of consumer platforms, including the €4.1 billion purchase of Just Eat Takeaway, it has rarely touched healthtech, and it is treating Alan as the base of a broader life-assistant ecosystem rather than a one-off bet. The offer to Alan is distribution: access to Prosus’s network and its commerce AI in markets where Alan is an unknown name. The risk in that offer is the same as the opportunity, because a French insurer’s edge has always been its obsessive product and its regulatory roots at home, and neither of those travels in a Prosus integration.

Why a French round this size is its own kind of news

The wider frame is the one Europe keeps having to relearn. French startup funding fell about 5% in 2025, and large late-stage cheques remain scarce across the continent, where startups raised a fraction of what their American peers did. A €480 million round for a profitable, decade-old company is exactly the deal Europe has struggled to produce, the late-stage, balance-sheet-heavy financing that usually requires an American or Gulf anchor to get done. Here the anchor is Dutch, the company is French, and the secondary component means some early believers are taking real money off the table rather than waiting for an IPO that European markets rarely reward.

Insurance pays out when things go wrong. Alan has raised €480 million on the wager that the better business, and eventually the bigger one, is in quietly making sure they go wrong less often, and it now has three months of valuation history and a balance sheet daring it to prove that the word “prevention” can be made to pay.